Send to

Choose Destination
Ther Clin Risk Manag. 2015 May 13;11:779-91. doi: 10.2147/TCRM.S71076. eCollection 2015.

The role of delamanid in the treatment of drug-resistant tuberculosis.

Author information

Tropical and Infectious Disease Unit, Royal Liverpool University Hospital, Liverpool, UK.
Liverpool School of Tropical Medicine, Pembroke Place, Liverpool, UK ; Liverpool Heart and Chest Hospital, Liverpool, UK.


Tuberculosis (TB) remains a significant cause of death worldwide, and emergence of drug-resistant TB requires lengthy treatments with toxic drugs that are less effective than their first-line equivalents. New treatments are urgently needed. Delamanid, previously OPC-67863, is a novel drug of the dihydro-nitroimidazole class with potent anti-TB activity and great promise to be effective in the treatment of drug-resistant TB. This review examines the preclinical and clinical development of delamanid, reviews current guidance on its use and evaluates the opportunities and challenges for its future role in TB management.


MDR-TB; OPC-67683; delamanid; drug resistance; tuberculosis

Supplemental Content

Full text links

Icon for Dove Medical Press Icon for PubMed Central
Loading ...
Support Center